knowledge -WSS

knowledge

author：fashion 2025-10-01 17:57:34 - browse：7454

Bernard Moss, a research scientist at NIAID. -- Infectious disease coverage from STAT — Bernard Moss Courtesy NIAID

For more than half a century, scientist Bernard Moss has been commanding the attention of peers interested in prying biological secrets from poxviruses and other microbiological targets. Now he’s commanding the attention of a different audience: House Republicans.

Moss, who will mark his 86th birthday in late July and who goes by Bernie, has worked for more than 55 years in the laboratories of the National Institute of Allergy and Infectious Diseases in Bethesda, Md. Over that time, he has been investigating viruses in relative anonymity — except, that is, among the virological cognoscenti.

But last year, in an interview with Science, Moss said he planned to try to determine why one strain of mpox viruses, known as Clade 1, is so much more virulent than those in a second strain, Clade 2, by taking genes from the former and putting them into the latter. Clade 2 viruses are responsible for the ongoing mpox outbreak first detected in May 2022.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Allen Institute goes after foundational questions, CEO Costa says

focus

WSS

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Profiling embryos to choose those with higher IQs is almost a reality

Profiling embryos to choose those with higher IQs is almost a reality

Hospital chaplains balance Covid safety with patients’ spiritual needs

Is it ever OK for doctors to lie to their patients?

PBM executives asked to testify by House panel

explore

knowledge

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Gene therapy denied for Afghan refugee whose father aided U.S.

Medical records are filled with copy

Is it ever OK for doctors to lie to their patients?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The creative science of coining drug names

How to save PrEP access — and even expand it

Arena BioWorks launches in Cambridge to speed drug discovery

In age of alternative facts, a scholarly course on calling out crap

PBM executives asked to testify by House panel

explore

Medicare Advantage overpayments discussion gets experts fired up

Arena BioWorks launches in Cambridge to speed drug discovery

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Merck to acquire Harpoon Therapeutics for $680 million

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

PBM executives asked to testify by House panel

explore

focus

focus

hotspot